Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo

Executive Summary

Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.

You may also be interested in...

Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin

Merck’s focus has shifted increasingly to Keytruda and immuno-oncology, while the company’s older stalwarts like Zetia, Vytorin and Januvia face pressure.

Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge

FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.

ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2

Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts